(Q53859491)

21 May 2018

title

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. (English)

1 reference

21 May 2018

1 reference

1 reference

1 reference

6

Alan W Partin

1 reference

21 May 2018

7

Jonathan I Epstein

1 reference

21 May 2018

author name string

Theresa Y Chan

1

1 reference

21 May 2018

Stephen D Mikolajczyk

2

1 reference

21 May 2018

Kristin Lecksell

3

1 reference

21 May 2018

Matthew J Shue

4

1 reference

21 May 2018

Harry G Rittenhouse

5

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 July 2003

1 reference

21 May 2018

published in

Urology

1 reference

21 May 2018

volume

62

1 reference

21 May 2018

issue

1

1 reference

21 May 2018

page(s)

177-181

1 reference

21 May 2018

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

Free prostate-specific antigen in serum is becoming more complex

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

Correlation of serum prostate specific antigen and quantitative immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900138-9

7 January 2021

10.1016/S0090-4295(03)00138-9

Identifiers

DOI

1 reference

21 May 2018

1 reference

21 May 2018